← board
IMMP
distress 1/10 · well-funded / low risk$0.39+0%today-88% from 52w high
Revenue
pre-revenue
Liquidity
$99M
Runway
—
Shares 1y
-52%
Price & events
-86.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.5%
1D
-10.9%
1W
+0.5%
1M
-31.2%
3M
-87.6%
6M
-76.7%
1Y
-80.8%
2Y
-88.9%
5Y
-87.3%
All
Overview
- Market Cap
- $572.33M
- Enterprise Value
- $500.54M
- Volume
- 44.93K
- 52 Week Range
- $0.31 – $3.18
- Total Shares
- 1.46B
- Float Shares
- 143.03M
- Short %
- 2.72%
- % Held by Insiders
- 0.01%
- % Held by Institutions
- 2.43%
- RVOL
- 0.12x
- Beta
- 2.22
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,460,389,575 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-17Maxim GroupHold → Buy
- 2026-03-13CitizensMarket Outperform → Market Perform
- 2026-03-13BairdOutperform → Neutral
- 2026-02-23CitizensMarket Outperform
- 2026-02-17CitizensMarket Outperform
- 2024-11-15BairdOutperform
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.